Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies

Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis | In-depth Insights into the Clinical Trials, Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Competitive Landscape, Key Companies
Delveinsight Business Research LLP
As per DelveInsight’s assessment, about 25+ key pharma and biotech companies are working on 25+ pipeline drugs in the Post-Traumatic Stress Disorder therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Post-Traumatic Stress Disorder (PTSD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Post-Traumatic Stress Disorder Market. 

The Post-Traumatic Stress Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases.  The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Post-Traumatic Stress Disorder Pipeline Analysis

Post-Traumatic Stress Disorder (PTSD) Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights into the emerging therapies for the treatment of Post-Traumatic Stress Disorder and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Post-Traumatic Stress Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

  • Late stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage products (Phase I) 

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

 Mechanism of Action of the Emerging Pipeline Therapies

  • Dopamine D2 receptor partial agonist action

  • Monoacylglycerol lipase inhibitor

  • Fatty acid amide hydrolase inhibitor

  • Alpha7 nicotinic acetylcholine receptor antagonist

  • NMDA receptor modulator

  • Brain derived neurotrophic factor modulator

  • Serotonin 2A receptor agonist

Route of Administration

Post-traumatic stress disorders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Inhalation

  • Inhalation/Intravenous/Oral

  • Intranasal

  • Intravenous

  • Intravenous/ Subcutaneous

  • Oral

  • Oral/intranasal/subcutaneous

  • Parenteral

  • Subcutaneous

Molecule Type

Products have been categorized under various Molecule types, such as

  • Antibody

  • Antisense oligonucleotides

  • Immunotherapy

  • Monoclonal antibody

  • Peptides

  • Protein

  • Recombinant protein

  • Small molecule

  • Stem Cell

  • Vaccine

Learn How the Ongoing Clinical & Commercial Activities will Affect the Post-Traumatic Stress Disorder Therapeutic Segment @

Post-Traumatic Stress Disorder Therapeutics Landscape

Several major pharma and biotech companies are developing therapies for Post-traumatic stress disorders. Currently, Otsuka Pharmaceutical is leading the therapeutics market with its Post-traumatic stress disorders drug candidates in the most advanced stage of clinical development.

The Leading Players in the Post-Traumatic Stress Disorder (PTSD) Therapeutics Market Include:

  • Alto Neuroscience

  • Aptinyx

  • AstraZeneca

  • Bionomics Limited

  • Boehringer Ingelheim

  • GlaxoSmithKline

  • H. Lundbeck A/S

  • Jazz Pharmaceuticals

  • Nobilis Therapeutics

  • Otsuka Pharmaceutical Development & Commercialization, Inc.

  • Pfizer

  • Remedy

  • Sage Therapeutics

  • Tonix Pharmaceuticals, Inc.

  • Yale University

And Many Others

Post-traumatic stress disorders Emerging and Marketed Drugs Covered in the Report Include:

  • BNC210: Bionomics Limited

  • Brexpiprazole:  Otsuka Pharmaceutical Development & Commercialization

  • JZP150: Jazz Pharmaceuticals

  • Lu AG06466: H. Lundbeck A/S

  • NBTX-001 Xenon Inhaler: Nobilis Therapeutics

  • NYX-783: Aptinyx

  • Rexulti (brexpiprazole) and Zoloft (sertraline) combination: Otsuka Pharmaceutical

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Post-Traumatic Stress Disorder Current Treatment Patterns

4. Post-Traumatic Stress Disorder – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Post-Traumatic Stress Disorder Late Stage Products (Phase-III)

7. Post-Traumatic Stress Disorder Mid-Stage Products (Phase-II)

8. Post-Traumatic Stress Disorder Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Post-Traumatic Stress Disorder Discontinued Products

13. Post-Traumatic Stress Disorder Product Profiles

14. Key Companies in the Post-Traumatic Stress Disorder Market

15. Key Products in the Post-Traumatic Stress Disorder Therapeutics Segment

16. Dormant and Discontinued Products

17. Post-Traumatic Stress Disorder Unmet Needs

18. Post-Traumatic Stress Disorder Future Perspectives

19. Post-Traumatic Stress Disorder Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:


Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving pharmaceutical market today @ Pharmaceutical Partner Identification Solutions

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States